We exist to improve the lives
of everyone affected by epilepsy

The US FDA approves cannabidiol medicine Epidiolex for use in Lennox-Gastaut syndrome and Dravet syndrome

28 Jun 2018

On Monday 25 June, the US Food and Drug Administration (FDA) approved the new cannabis-based medicine Epidiolex for use in Lennox-Gastuat syndrome (LGS) and Dravet syndrome.

GW Pharmaceuticals’ medicine has been approved for use for the two rare and severe forms of epilepsy in two-year-olds and above. According to reports, it is set to become available in the US in the autumn.

A decision is expected from the European Medicines Agency (EMA) on the use of Epidiolex in the UK and Europe early next year. If approved, the medicine will become available a little later in the year.

The medicine is made from a part of the cannabis plant called cannabidiol (CBD). This does not contain the part of the cannabis plant that creates a ‘high’.

CBD has recently undergone a number of clinical trials to assess its effectiveness and safety when treating LGS and Dravet syndrome. It has been shown to have beneficial effects in treating both of these forms of epilepsy.

The FDA said the most common side-effects from the Epidiolex clinical trials included sleepiness, loss of appetite and diarrhoea. People also sometimes experienced a rash, weakness, poor quality sleep, infections and an impact on the liver.

FDA commissioner Dr Scott Gottlieb said that thorough clinical trials and careful review is the most appropriate way to bring cannabis-based treatments to people.

Dr Billy Dunn, director of the Division of Neurology Products at the FDA said that the seizures in people with Drave syndrome or LGS have “a profound impact on these patients’ quality of life”.

Reports say this is the first ever medicine approved specifically for treating Dravet syndrome.

There is more information on the rare epilepsy syndromes on the Epilepsy Action website. You can also find on the website Epilepsy Action’s position statements on cannabis-based medicines.

 

You may also be interested in…

UK government to review use of medicinal cannabis

A review into the use of medicinal cannabis was announced by the Home Office yesterday at the House of Commons.

There are no comments yet. Be the first to comment...

Question about your epilepsy?

Use our email helpline service -- your question will be sent directly to our trained helpline advisors who will reply to you. If you post a question about your epilepsy as a comment on a page, it may not be replied to so please use the email helpline service.

Want to talk to other people with epilepsy?

Take a look at forum4e our online community for people with epilepsy. Anyone with epilepsy over the age of 16 can join, from anywhere in the world.

Comment about this page?

We welcome feedback on the content of our website. If you have any comments about the page you were reading, then please complete the form below.

All comments are reviewed by a moderator before appearing on the site. Once the comment appears, your name and comment will be seen by other visitors to the site. Comments will be edited or deleted if they are offensive, libellous, slanderous, abusive, commercial or irrelevant. Comments may also be edited or deleted if they are not relevant to the page on which they are entered.

We ask for your email when you make a comment through this website. This means that we can let you know directly that we have replied to you. By making a comment through the website, you allow us to use the comment in our publicity without using your name. If we would like to use your name, we will email you to get your permission.

The content of this field is kept private and will not be shown publicly.
CAPTCHA
This question is for testing whether you are a human visitor and to prevent automated spam submissions.